Personal Information
Organization / Workplace
Ahmedabad Area, India India
Occupation
Professor Emeritus, Institute of Pharmacy, Nirma University
Industry
Medical / Health Care / Pharmaceuticals
About
Prof. (Dr.) Bhaswat S. Chakraborty graduated with a B.Pharm. (Hons.) from Banaras Hindu University and a PhD in Pharmacology from University of Saskatchewan, Saskatoon, Canada.
Currently he is Professor Emeritus at Institute of Pharmacy, Nirma University. Before this, Dr. Chakraborty was Senior VP & Chair of R&D of Cadilapharma and President of Foresee Consultants,Toronto. Prior to that he was Director of Biopharmaceutics at Biovail International,Toronto. During 1989-1997,he was Senior Clinical Reviewer and Acting Department Head at Government of Canada (Canadian FDA) in Ottawa.
He has served at various other important academic,industry & government positions in Canada and USA.
Tags
bioequivalence
ct
clinicaltrials
drug discovery
clinical
clinical trials
replicate design
pharmacokinetics
plasma proteins drugs clinical
quality
biosimilars
pk
pharmacovigilance
corrective and preventive action
root cause analysis
outliers
two period crossover
respiratory pbpk
mdi
orally inhaled
ivpt
ivrt
non=linear
mrdfs
fed studies
parallel
crossover
complex generics
gdufa ii
primary objective
pivotal
medical devices
clinical trial
style
grammar
technical writing
efficacy
safety
clinical pharmacology
us fda
bla
nda
newton
inter-personal
intra-personal
adaptation
bpharm
mpharm
five ways to stop plagiarism
root cause
anti-plagiarism softwares
originality
plagiarism
risk based approaches
data integrity
bioethics
clinical research
pharmacy
ethics
pre-clinical.
pharmacists
development
regulatory
non-clinical
biosimilar
phase ii trials
cancer
acceptance limits
confidence intervals
drug-products
data
integrity
fda patent exclusivity
gcp
glp
india
fda
risk management
career
science
average
polpulation
individual
drug delivery system
cancer ct
phase ii
go no go
bayesian
toxic signals
nanotechnology
See more
Presentations
(93)Documents
(24)Likes
(1)GLP in Bioequivalence Studies
Bhaswat Chakraborty
•
10 years ago
Personal Information
Organization / Workplace
Ahmedabad Area, India India
Occupation
Professor Emeritus, Institute of Pharmacy, Nirma University
Industry
Medical / Health Care / Pharmaceuticals
About
Prof. (Dr.) Bhaswat S. Chakraborty graduated with a B.Pharm. (Hons.) from Banaras Hindu University and a PhD in Pharmacology from University of Saskatchewan, Saskatoon, Canada.
Currently he is Professor Emeritus at Institute of Pharmacy, Nirma University. Before this, Dr. Chakraborty was Senior VP & Chair of R&D of Cadilapharma and President of Foresee Consultants,Toronto. Prior to that he was Director of Biopharmaceutics at Biovail International,Toronto. During 1989-1997,he was Senior Clinical Reviewer and Acting Department Head at Government of Canada (Canadian FDA) in Ottawa.
He has served at various other important academic,industry & government positions in Canada and USA.
Tags
bioequivalence
ct
clinicaltrials
drug discovery
clinical
clinical trials
replicate design
pharmacokinetics
plasma proteins drugs clinical
quality
biosimilars
pk
pharmacovigilance
corrective and preventive action
root cause analysis
outliers
two period crossover
respiratory pbpk
mdi
orally inhaled
ivpt
ivrt
non=linear
mrdfs
fed studies
parallel
crossover
complex generics
gdufa ii
primary objective
pivotal
medical devices
clinical trial
style
grammar
technical writing
efficacy
safety
clinical pharmacology
us fda
bla
nda
newton
inter-personal
intra-personal
adaptation
bpharm
mpharm
five ways to stop plagiarism
root cause
anti-plagiarism softwares
originality
plagiarism
risk based approaches
data integrity
bioethics
clinical research
pharmacy
ethics
pre-clinical.
pharmacists
development
regulatory
non-clinical
biosimilar
phase ii trials
cancer
acceptance limits
confidence intervals
drug-products
data
integrity
fda patent exclusivity
gcp
glp
india
fda
risk management
career
science
average
polpulation
individual
drug delivery system
cancer ct
phase ii
go no go
bayesian
toxic signals
nanotechnology
See more